TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16148557
Drug: Oral norfloxacin
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral norfloxacin (25 patients)
Study: 16148557
Drug: Intravenous ampicillin/sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ampicillin/sulbactam (21 patients)
Study: 12166344
Drug: Niceritrol 750‐1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niceritrol 750‐1500 mg/day + Pravastatin 10 mg/day (after 8 weeks)
Study: 12166344
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg/day + Niceritrol 750‐1500 mg/day (after 8 weeks)
Study: 12166344
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Niceritrol + Pravastatin)
Study: 8292907
Drug: Cocos nucifera
Normalized name: COCOS NUCIFERA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocos nucifera pollen extract immunotherapy (CPE‐IT)
Study: 3052814
Drug: d-fenfluramine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-fenfluramine (30 mg/day)
Study: 3052814
Drug: d-fenfluramine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-fenfluramine (single dose of 0, 30, 40, and 60 mg)
Study: 24796047
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group treated with pinaverium (50 mg, 3 times a day) and live combined bifidobacterium and lactobacillus tablet (4 tablets, 3 times a day) for 4 weeks
Study: 18208917
Drug: Non-opioid analgesics
Normalized name: Non-opioid analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid analgesics (n=13)
Study: 12697633
Drug: Piperacillin-tazobactam, 3.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam, 3.375 g every 6 h
Study: 15150184
Drug: Ceftriaxone, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone, 1 g once a day
Study: 12536743
Drug: FU (1
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FU (1 mg.kg‐1) combination with sham infusion
Study: 12536743
Drug: FU (1
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FU (1 mg.kg‐1) combination with 50 ml of 20% solution of Albumin
Study: 12536743
Drug: FU (1
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FU (1 mg/kg) combination with 250 ml dextran 40
Study: 12536743
Drug: FU (1
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FU (1 mg.kg‐1) combination with Albumin
Study: 12536743
Drug: FU (1
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FU (1 mg/kg) combination with dextran 40
Study: 8355942
Drug: Clindamycin vaginal
Normalized name: clindamycin Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin vaginal cream 2% (5 g intravaginally at bedtime for 7 days)
Study: 8355942
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg (two 250-mg capsules orally twice a day for 7 days)
Study: 8355942
Drug: Clindamycin vaginal
Normalized name: clindamycin Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin vaginal cream 2%
Study: 3471750
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg
Study: 3549923
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of berberine sulfate (BS) in a single oral dose for ETEC diarrhea
Study: 3549923
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of berberine sulfate (BS) for ETEC diarrhea
Study: 3549923
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of berberine sulfate (BS) for cholera
Study: 3549923
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg of berberine sulfate (BS) plus tetracycline for cholera
Study: 30167954
Drug: Ilaprazole 20
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 20 mg daily for 8 weeks
Study: 30167954
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg daily for 8 weeks
Study: 27793818
Drug: Intravenous cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cefazolin and oral ciprofloxacin for 3 days
Study: 27793818
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin and oral cefuroxime for 3 days
Study: 11148512
Drug: Nebulized ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized ipratropium bromide (IB) 250 microg combined with 2.5 mg albuterol by jet nebulization.
Study: 11148512
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group received isotonic saline solution substituted for IB.
Study: 9351559
Drug: PSA in
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA in combination with digital rectal examination
Study: 7513718
Drug: 12-h iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-h iv GH infusion (1 IU/h)
Study: 7513718
Drug: 2-day sc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-day sc GH treatment (8 IU/day) followed by 12-h iv infusion of GH (1 IU/h)
Study: 7513718
Drug: Regular daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular daily sc GH therapy (3 IU/m2.day)
Study: 7513718
Drug: 12-h iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-h iv saline infusion
Study: 7513718
Drug: No GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: No GH (after discontinuation of GH for 2 days)
Study: 30683087
Drug: COM-B questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: COM-B questionnaire administered to TB health workers
Study: 27840330
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (30 mg IV bolus and 1 mg/kg subcutaneous dose)
Study: 25724860
Drug: Nebulized colistin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized colistin 1 million IU twice a day for one year
Study: 18334782
Drug: Ropivacaine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (7.5 mg/ml)
Study: 20171481
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution (placebo)
Study: 10984373
Drug: Budesonide nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide nasal spray and Placebo
Study: 8799514
Drug: 619C89 (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 619C89 (0.5, 1, 1.5, 2, 2.5 mg kg‐1 loading infusions followed by 0.25, 0.5, 0.75, 1, 1.25 mg kg‐1 maintenance infusions)
Study: 1847648
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy with cyclophosphamide (10 G m‐2), ifosfamide (11 G m‐2), mitomycin C (70 mg m‐2), mustine (30 mg m‐2)
Study: 1847648
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy with cisplatin (100 mg m‐2), ifosfamide (11 G m‐2), mitomycin C (70 mg m‐2), mustine (30 mg m‐2)
Study: 6335905
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of BGP with parathyroid hormone
Study: 30555165
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine (LDAC) alone
Study: 31462554
Drug: Stop NA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop NA therapy for 72 weeks
Study: 31462554
Drug: Continue NA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue NA therapy for 72 weeks
Study: 31462554
Drug: Stop NA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop NA therapy
Study: 31462554
Drug: Continue NA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue NA therapy
Study: 30150460
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg MEDI8852 plus 75 mg oseltamivir
Study: 30150460
Drug: 3,000 mg
Normalized name: ascorbic acid/minerals 3,000 mg ORAL POWDER IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,000 mg MEDI8852 plus 75 mg oseltamivir
Study: 30150460
Drug: 3,000 mg
Normalized name: ascorbic acid/minerals 3,000 mg ORAL POWDER IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,000 mg MEDI8852 alone
Study: 30150460
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus 75 mg oseltamivir
Study: 27793183
Drug: Sequential training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential training (SEQ)
Study: 23616514
Drug: 1.0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g/d L-tryptophan
Study: 23616514
Drug: 2.0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g/d L-tryptophan
Study: 23616514
Drug: 3.0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g/d L-tryptophan
Study: 23616514
Drug: 4.0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 g/d L-tryptophan
Study: 23616514
Drug: 5.0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 g/d L-tryptophan
Study: 10232640
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 g/d)
Study: 22446172
Drug: Benfotiamine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfotiamine (300 mg/day)
Study: 20158623
Drug: Lifestyle factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle factors including drug usage patterns
Study: 10422925
Drug: ANH (blinded,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANH (blinded, placebo injections)
Study: 2104081
Drug: Tripotassium dicitrato
Normalized name: Tripotassium dicitratobismuthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripotassium dicitrato bismuthate (TDB) maintenance therapy (120 mg Bi2O3, one swallow tablet nocte)
Study: 692577
Drug: Solution or
Normalized name: Quindal Solution Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution or uncoated tablets
Study: 692577
Drug: Sustained-release formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release formulations (3 of 6)
Study: 692577
Drug: Sustained-release formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release formulations (3)
Study: 692577
Drug: Uncoated tablets
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uncoated tablets
Study: 25680689
Drug: Guanidinoacetic acid
Normalized name: Guanidinoacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanidinoacetic acid (GAA) 3 grams daily for 3 weeks
Study: 23755929
Drug: ER tramadol
Normalized name: tramadol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER tramadol 200 mg
Study: 23755929
Drug: ER tramadol
Normalized name: tramadol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER tramadol 600 mg
Study: 20934556
Drug: Edoxaban high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban high exposure (60 mg daily, adjusted for drug clearance)
Study: 20934556
Drug: Edoxaban low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban low exposure (30 mg daily, adjusted for drug clearance)
Study: 20934556
Drug: Warfarin titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin titrated to an international normalized ratio of 2.0 to 3.0
Study: 1616967
Drug: Metronidazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (400 mg twice daily for 7 days)
Study: 30208601
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (Ca-antagonists)
Study: 10373219
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors (ACE-I)
Study: 22828694
Drug: Thoracic intraarticular
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic intraarticular injections
Study: 12011609
Drug: Fluoxetine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (n = 13)
Study: 10449104
Drug: Lenercept (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenercept (10, 50, or 100 mg IV every 4 weeks for up to 48 weeks)
Study: 8960851
Drug: ramipril (2.5‐5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril (2.5‐5.0 mg/day)
Study: 24576401
Drug: Oral lipid-tolerance
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lipid-tolerance test meal
Study: 11960154
Drug: Dexamethasone (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.6 mg/kg/day in 4 divided doses for first 4 days)
Study: 9707026
Drug: Foscarnet 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet 90 mg/kg every 12 h for 15 days
Study: 9707026
Drug: Ganciclovir 5
Normalized name: ganciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir 5 mg/kg every 12 h for 15 days
Study: 7631132
Drug: IVR 400
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVR 400 micrograms.kg-1 plus DEC 6 mg.kg-1
Study: 7631132
Drug: DEC 6
Normalized name: Zodryl DEC 60 Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC 6 mg.kg-1
Study: 7508065
Drug: Indapamide 2.5
Normalized name: indapamide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 2.5 mg daily
Study: 31713733
Drug: Tripterygium wilfordii
Normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium wilfordii Hook F (TwHF) 40-60 mg/day
Study: 31713733
Drug: Cyclophosphamide (CYC)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CYC) 100 mg/day
Study: 29856176
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine with morphine plus nalbuphine (Group 2)
Study: 29856176
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine with morphine (Group 1)
Study: 24168638
Drug: Online personal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online personal activity monitor (Gruve Solution™)
Study: 17709060
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (50 min, twice weekly for 4 weeks)
Study: 17709060
Drug: Guided relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided relaxation (50 min, twice weekly for 4 weeks)
Study: 9687407
Drug: Moxifloxacin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 50 mg
Study: 9687407
Drug: Moxifloxacin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 100 mg
Study: 9687407
Drug: Moxifloxacin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 200 mg
Study: 9687407
Drug: Moxifloxacin 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 600 mg
Study: 2686488
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group K) - saline solution
Study: 2686488
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg fentanyl (group 0,1F)
Study: 2686488
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg fentanyl (group 0,2F)
Study: 2686488
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg fentanyl (group 0,3F)
Study: 2686488
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg nifedipine (group 1,0N)
Study: 2686488
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg nifedipine + 0.1 mg fentanyl (group 0,5N + 0,1F)
Study: 2686488
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg nifedipine + 0.1 mg fentanyl (group 1,0N + 0,1F)
Study: 326638
Drug: Metiamide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metiamide (400 mg)
Study: 25464260
Drug: Short-term antihypertensive
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term antihypertensive treatment (median follow-up of 20 days)
Study: 19126368
Drug: No epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: No epidural steroid injection (Control)
Study: 17955651
Drug: Electroacupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture plus acupoint-injection
Study: 16020985
Drug: oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration of trimetazidine, prednisolone, and vitamin B complex
Study: 16020985
Drug: intravenous piracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous piracetam and prednisolone
Study: 16020985
Drug: further treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: further treatment with trimetazidine for a month
Study: 16020985
Drug: timely initiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: timely initiation of therapy within the first week following acoustic trauma
Study: 16020985
Drug: degree of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: degree of hearing improvement after medication
Study: 11674925
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg daily for 4 weeks after a 2 week placebo period
Study: 7889958
Drug: Cefprozil 20
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefprozil 20 mg/kg once daily
Study: 7889958
Drug: Cefprozil twice
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefprozil twice daily
Study: 7889958
Drug: Cefprozil once
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefprozil once daily
Study: 27323347
Drug: Zoledronate 4
Normalized name: zoledronic acid 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronate 4 mg i.v. for 5 years, administered every 4 weeks for the first 6 months, every 3 months for the following 2 years, and every 6 months for the last 2.5 years.
Study: 24121220
Drug: Bio-electro-magnetic-regulation treatment
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-electro-magnetic-regulation treatment
Study: 24121220
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Bio-electro-magnetic-regulation treatment + Pentoxifylline infusions)
Study: 18240145
Drug: Simultaneous castration
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous castration plus HTI-286 therapy
Study: 16373903
Drug: Insulin analog
Normalized name: insulin analog, glargine 300 UNT Pen Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin analog
Study: 11221123
Drug: Home visits
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home visits to non-returners after treatment.
Study: 8817142
Drug: Heparin-coated CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated CPB circuit with reduced systemic heparinization (ACT > 250 s) (n = 17)
Study: 8817142
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with uncoated circuits and full heparin dose (ACT > 480 s) (n = 16)
Study: 1306211
Drug: Pirenzepine (M1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (M1 muscarinic antagonist)
Study: 1306211
Drug: Biperiden (M1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden (M1 muscarinic antagonist)
Study: 31661850
Drug: Treatment A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: 140 mg of ZynamiteÂ®, 140 mg of quercetin, 147.7 mg of maltodextrin, and 420 mg of sunflower lecithin
Study: 31661850
Drug: Treatment B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B: 140 mg of ZynamiteÂ®, 140 mg of quercetin, and 2126 mg of maltodextrin
Study: 31661850
Drug: Treatment C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C: 2548 mg of maltodextrin (placebo)
Study: 26787023
Drug: Power whitening
Normalized name: NIACINAMIDE 2 g in 100 mL TOPICAL CREAM [DR.ALTHEA POWER WHITENING GLUTATHIONE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Power whitening gel (38% Hydrogen Peroxide)
Study: 19733931
Drug: Customized chemotherapy
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Customized chemotherapy based on ERCC1 mRNA expression for patients with low levels of ERCC1 (docetaxel/cisplatin) and high levels of ERCC1 (docetaxel/gemcitabine)
Study: 18585496
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin plus routine use of GP IIb/IIIa inhibitors
Study: 14618108
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - micronized estradiol: 1 mg/day, progesterone: 0.25 mg/day
Study: 11095120
Drug: Ketorolac-tobramycin combination
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ketorolac-tobramycin combination
Study: 11095120
Drug: Fluorometholone-tobramycin combination
Normalized name: fluorometholone / tobramycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorometholone-tobramycin combination
Study: 1467386
Drug: m-chlorophenylpiperazine (mCPP)
Normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-chlorophenylpiperazine (mCPP) 0.35 mg/kg
Study: 6369215
Drug: Balanced Salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced Salt Solution (BSS)
Study: 30240280
Drug: 40% ASiR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% ASiR at normal dose (NI 10-40%)
Study: 30240280
Drug: 40% ASiR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% ASiR at low dose (NI 20-40%)